Recruiting studies: Unresectable Leiomyosarcoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Phase 2 · 1 location(s) · Fudan University · NCT06849986 Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Adv
Phase 1 · 16 location(s) · National Cancer Institute (NCI) · NCT05711615 A Study of Ivonescimab in People With Leiomyosarcoma
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07516925 XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Tran
Phase 2 · 1 location(s) · Northwestern University · NCT06571734

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.